alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Crop Improvement and Protection Research: Salinas, CA
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    CareersSearch small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Pacific West Area Salinas, California Crop Improvement and Protection Research People & Locations







Saben  Kane
                        Crop Improvement and Protection Research

                        




                        
                        Biological Science Lab Technician
                        Phone: (831) 755-2879
                        
                        
                        Fax: (Employee information on this page comes from the REE Directory. Please contact your front office staff to update the REE Directory.)
                            **Publications**
                                                (Clicking on the reprint icon
                                                    Reprint Icon
                                                    will take you to the publication reprint.)Post-fumigation survival of soilborne pathogens of strawberry and lettuce

- (Abstract Only)Quantification of Fusarium oxysporum disease potential from soil DNA

- (Proceedings)Matson, M.E., Crouch, U., Kane, S.M., Henry, P.M., Goldman, P.H., Martin, F.N. 2020. Quantification of Fusarium oxysporum disease potential from soil DNA. Methyl Bromide Alternatives Outreach (MBAO) Conference, November 3-5, 2020 (virtual).


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov
Merrill Schneider, OSB #77336 

merrillschneider@schneiderlaw.com 

Schneider Kerr & Robichaux 

PO Box 14490 

Portland, Oregon 97293 

Phone: 503-255-9092 

Fax: 503-255-9145 

Attorney for Plaintiff 

IN THE UNITED STATES DISTRICT COURT 

FOR THE DISTRICT OF OREGON 

MICHAEL BRANDON WILLIAMS, 

 Plaintiff, 

v. 

COMMISSIONER OF SOCIAL SECURITY, 

 Defendant. 

3:14-CV-01878-YY

ORDER FOR ATTORNEY 

FEES UNDER 42 U.S.C. § 406(b) 

The court finds and orders an attorney fee of $7,475.71 pursuant to 42 U.S.C. § 406(b). 

The attorney fee of $1,826.34 allowed pursuant to the Equal Access to Justice Act was seized by 

the Treasury, and thus will not be refunded to Plaintiff. 

Dated this _______ day of ____________________, 2018. 

________________________________ 

Youlee Yim You

United States Magistrate Judge 

14th December
CERTIFICATION
PURSUANT TO


18 U.S.C.
SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002





I,
John A. Poserina, Chief Executive Officer of Synergx Systems certify
that:





1.  I
have reviewed this annual report on Form 10-KSB/A of Synergx Systems
Inc.;





2.  Based
on my knowledge, this annual report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this annual
report;





3.
Based on my knowledge, the financial statements, and other financial information
included in this annual report, fairly present in all material respects the
financial condition, results of operations and cash flows of registrant as of,
and for, the periods presented in this annual report;





4.  The
registrant’s other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-14 and 15d-14) for the registrant and have:





a)  Designed
such disclosure controls and procedures, or caused such  disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this annual report is being prepared;





b)  Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and
presented in this annual report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period cover by this
report based on such evaluation; and





c)  Disclosed
in this annual report any change in the registrant’s internal control over
financial reporting that occurred during registrant’s most recent fiscal quarter
that has materially affected, or reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and





5.  The
registrant’s other certifying officers and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors
(or persons performing the equivalent functions);





a)
All significant deficiencies in material weakness the design or operation of
internal controls over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and
report financial information; and





b)  Any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant’s internal control over financial
reporting.





Date:
      January
      28, 2009
                By:
                /s/ John
      A. PoserinaJohn
      A. PoserinaTreasurer,
      Vice President,Chief
      Financial Officer,Secretary
      and Director(Principal
      Financial Officer)
<PAGE>


                                                                   Exhibit 99.18

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Eurotech Ltd. (the "Company") on Form
10-Q for the period ending September 30, 2002 as filed with the Securities and
Exchange Commission on the date hereof (the "Report"), I, Don V. Hahnfeldt,
Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350,
as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

         (1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.

/s/ Don V. Hahnfeldt
--------------------
Don V. Hahnfeldt
Chief Executive Officer
November 19, 2002
Exhibit 99.2



THANKSGIVING COFFEE COMPANY, INC.



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Quarterly Report of Thanksgiving Coffee Company, Inc. (the Company) on Form 10-Q for the quarter ended March 31, 2003
as filed with the Securities and Exchange Commission on the date hereof (the Report), I, the undersigned Chief Financial Officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:



| | (i) |  | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- |  | ---------------------------------------------------------------------------------------------------------------------



| | (ii) |  | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| | ---- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------



/s/    JOAN
KATZEFFPresident and Chief Financial Officer




May 7, 2003
[Federal Register Volume 86, Number 158 (Thursday, August 19, 2021)]
[Notices]
[Pages 46707-46708]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17821]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Cancer 
Institute Clinical Trials and Translational Research Advisory 
Committee.
    The meeting will be held as a virtual meeting and is open to the 
public. Individuals who plan to view the virtual meeting and need 
special assistance or other reasonable accommodations to view the 
meeting, should notify the

[[Page 46708]]

Contact Person listed below in advance of the meeting. The meeting will 
be videocast and can be accessed from the NIH Videocasting and 
Podcasting website (http://videocast.nih.gov).

    Name of Committee: National Cancer Institute Clinical Trials and 
Translational Research Advisory Committee.
    Date: November 10, 2021.
    Time: 11:00 a.m. to 3:00 p.m.
    Agenda: Strategic Discussion of NCI's Clinical and Translational 
Research Programs.
    Place: National Cancer Institute, 9609 Medical Center Drive, 
Rockville, MD 20850 (Virtual Meeting).
    Contact Person: Sheila A. Prindiville, M.D., M.P.H., Director, 
Coordinating Center for Clinical Trials, National Cancer Institute, 
National Institutes of Health, 9609 Medical Center Drive, Room 
6W136, Rockville, MD 20850, 240-276-6173, <a href="/cdn-cgi/l/email-protection#97e7e5fef9f3fee1e4d7faf6fefbb9f9feffb9f0f8e1"><span class="__cf_email__" data-cfemail="3747455e59535e4144775a565e5b19595e5f19505841">[email protected]</span></a>.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: August 16, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-17821 Filed 8-18-21; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
EXHIBIT 31.2

                       CERTIFICATION PURSUANT TO SECTION
                         302 OF THE SARBANES OXLEY ACT


I, Virgil Baker, certify that:

1. I have reviewed this annual report on Form 10-KSB of eTotalSource, Inc.;

2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this annual report is being prepared;

b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this annual
report (the "Evaluation Date"); and

c) presented in this annual report our conclusions about the effectiveness of
the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):

a) all significant deficiencies in the design or operation of internal controls
which could adversely affect the registrant's ability to record, process,
summarize and report financial data and have identified for the registrant's
auditors any material weaknesses in internal controls; and

<PAGE>

b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls; and

6. The registrant's other certifying officers and I have indicated in this
annual report whether there were significant changes in internal controls or in
other factors that could significantly affect internal controls subsequent to
the date of our most recent evaluation, including any corrective actions with
regard to significant deficiencies and material weaknesses.

Date:  April 13, 2004


/s/ Virgil Baker
-----------------------
Virgil Baker,
Secretary/Treasurer
# United States Court **of Appeals**  **f or the Fifth Circuit** 

**____________** No. 23 - 50578 Summary Calendar

**____________ United States of America,**  Plaintiff
— Appellee **,** versus **Ascencion Luna -**  **Hernandez,** Defendant
— Appellant **.**

**______________________________** Appeal from the United States District Court for the Western District of Texas USDC No. 2:22 - CR - 2199 - 1

**____________ __________________**  Before **Smith, Higginson,** and **Engelhardt,** Circuit Judges **. Per Curiam**  **:** ***** The attorney appointed to represent Ascencion Luna - Hernandez has moved to withdraw and has filed a brief per Anders v. California , 386 U.S. 738 (1967), and United States v. Flores , 632 F.3d 229 (5th Cir. 2011). Luna Hernandez has not filed a response. We have reviewed counsel’s brief and relevant portions of t he record.

**_____________________** * This opinion is not designated for publication. See **5th Cir .**  **R .**  47.5. United States Court of Appeals Fifth Circuit 

### FILED May 29, 2024 Lyle W. Cayce Clerk Case: 23-50578 Document: 57-1 Page: 1 Date Filed: 05/29/2024No. 23 - 50578

2 We concur with counsel’s assessment that the appeal presents no non frivolous issue for appellate review. Accordingly, the motion to withdraw is **GRANTED** , counsel is excused from further responsibilities herein, and the appeal is **DISMISSED** . See **5th Cir. R.** 42.2 . Case: 23-50578 Document: 57-1 Page: 2 Date Filed: 05/29/2024
<PAGE>

                                                                 EXHIBIT 10.9(b)

                             Go-Gro Industries Ltd.
   6/F. Kenning Industrial Building, 19 Wang Hoi Road, Kowloon Bay, Hong Kong
        Tel: 2798 9128 (16 Lines) Fax: 2422 9275 / 2798 0869 / 2422 9301

July 20, 1999

Mr. Qian Fu Ming
Director
Shunde No. 1 Lamps Factory
Shunfeng Industrial District
Shunfenshan Shunde County
Guangdong Province, China

RE:   Go-Gro Limited and/or Its Subsidiaries and Its Affiliates ("Go-Gro")

Gentlemen:

We are pleased to confirm our agreement pursuant to which Shunde No. Lamp
Factory ("Shunde") has agreed to manufacture for Go-Gro on an exclusive agency
basis all lighting products to be sold into North and South America and the
European Community for a three year period beginning October 1, 1999 (in
addition, Shunde agrees not to quote any Go-Gro customers in North and South
America and/or the European Community during said three year period). In
consideration for Shunde granting Go-Gro such an exclusive arrangement, Go-Gro
agrees to strive to purchase during each year during the three year period,
1200-1300 containers of lighting products.

This letter will also confirm that in the event Go-Gro does not purchase a
minimum of 1200 containers each year, Shunde shall have the option to sell
lighting products to non-Go-Gro customers in North and South America and the
European Community during the subsequent 12 month period.

We certainly appreciate doing business with you and look forward to continuing
our valuable relationship. Please confirm your agreement as to the terms of this
letter by signing the enclosed copy of this letter and returning it to me at
your earliest convenience.

                                        Very truly yours,


                                        /s/ Jackey Chu
                                        ----------------------------------------
                                        Jackey Chu
                                        President


                                        /s/ Robert Hersh
                                        ----------------------------------------
                                        Robert Hersh
                                        Chairman

cc: George Branham

ACCEPTED AND AGREED
SHUNDE NO. 1 LAMP FACTORY


By: /s/ Qian Fu Ming
    ---------------------------------
    Mr. Qian Fu Ming, Director
1

The Honorable Stephen M. Reasoner, Chief Judge, United States

District Court for the Eastern District of Arkansas, adopting the

report and recommendations of the Honorable John F. Forster, Jr.,

United States Magistrate Judge for the Eastern District of

Arkansas.

___________

No. 96-1729

___________

Merlin Hagen, *

 *

Appellant, *

 *

v. * Appeal from the United States

 * District Court for the

Larry Norris, Director, * Eastern District of Arkansas.

Arkansas Department of *

Correction, * [UNPUBLISHED]

 *

Appellee. *

___________

 Submitted: December 12, 1996

 Filed: December 16, 1996 ___________

Before FAGG, WOLLMAN, and MURPHY, Circuit Judges. ___________

PER CURIAM.

Merlin Hagen, an Arkansas inmate, appeals from the district

court's1 order dismissing his 28 U.S.C. § 2254 habeas petition. We

have carefully reviewed the record and the parties' submissions on

appeal, and conclude that the district court's decision was clearly

correct, and that an extended discussion is not warranted. Hagen's

pro se objection to no argument disposition of this case is denied.

The judgment is affirmed. See 8th Cir. R. 47B. 
-2-

A true copy.

Attest:

CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.
EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In
connection with the Annual Report on Form 10-K for the year ended December 31, 2004 (the "Report") by Bentley Pharmaceuticals, Inc. (the "Registrant"), the
undersigned hereby certifies that, to his knowledge:



| |  | /s/ James R. MurphyJames R. Murphy
Chairman of the Board of Directors,
President and Chief Executive Officer
(Principal Executive Officer)
| |  | ------------------------------------------------------------------------------------------------------------------------------------------
| |  | March 16, 2005                                                                                                                            

---



QuickLinks